Navigation Links
Sangamo BioSciences Reports First Quarter 2012 Financial Results
Date:5/2/2012

s and presentation of data from clinical trials. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the early stage of ZFP Therapeutic development, uncertainties related to the timing of initiation and completion of clinical trials, whether clinical trial results will validate and support the safety and efficacy of ZFP Therapeutics, and the ability to establish strategic partnerships.  Further, there can be no assurance that the necessary regulatory approvals will be obtained or that Sangamo will be able to develop commercially viable gene based therapeutics. Actual results may differ from those projected in forward-looking statements due to risks and uncertainties that exist in the company's operations and business environments. These risks and uncertainties are described more fully in the company's Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q as filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.SELECTED CONSOLIDATED FINANCIAL DATA(in thousands, except per share data)(unaudited)Three Months Ended Statement of Operations DataMarch 31, 20122011Revenues:Collaboration agreements

$ 1,663$ 1,487Research grants

1,579713Total revenues

3,2422,200Operating expenses:Research and development

7,2838,262General and administrative

3,2423,539Total operating expenses

10,52511,801Loss from operations

(7,283)(9,601)Interest and other income, net

1523Net loss

$ (7,268)$ (9,578)Basic and diluted net loss per common share

$ (0.14)$ (0.21)Shares used in computing basic and diluted net loss per common share

52,56745,461March 31, 2012December 31, 2011(Unaudited)Selected B
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Sangamo BioSciences to Present at the UBS Global Life Sciences Conference
2. Sangamo BioSciences to Present at Two Upcoming Investor Conferences
3. Sangamo BioSciences Announces Third Quarter Conference Call and Webcast
4. Sangamo BioSciences Presents Data at ICAAC Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
5. Sangamo BioSciences Reports Third Quarter 2008 Financial Results
6. Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601
7. Sangamo BioSciences Appoints Paul Cleveland to Its Board of Directors and Chair of Audit Committee
8. Sangamo BioSciences to Webcast Annual Investor and Analyst Briefing and Presentation at Piper Jaffray Health Care Conference
9. Sangamo BioSciences to Present at the 27th Annual J.P. Morgan Healthcare Conference
10. Sigma-Aldrich and Sangamo BioSciences Announce the Achievement of Key Throughput Milestone in Research Reagents Agreement
11. Sangamo BioSciences Announces Fourth Quarter and Year-End 2008 Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... Mich. , Aug. 27, 2015  Neogen Corporation ... acquired the stock of United Kingdom ... of microbiological culture media and diagnostic systems. ... grown into a leading provider of microbial testing and ... clinical testing markets. The company currently sells into more ...
(Date:8/27/2015)... -- HUYA Bioscience International (HUYA) today announced the sponsorship of ... HTLV-1, held this week at the University of Tokyo ... is to promote research on HTLV-1 and HTLV-1-associated diseases, ... research related to these fields to advance science, the ... to support this prestigious conference," said Mireille Gillings ...
(Date:8/27/2015)... CA (PRWEB) , ... August 27, 2015 , ... ... in Personalized Medicine, recently presented new data on the relationship of genetics and ... 20th World Congress on Heart Disease in Vancouver, British Columbia, Canada. The event, ...
(Date:8/26/2015)... , Aug. 26, 2015  The Diabetes Research ... University of Miami Miller School of Medicine, announced ... trial to test for the first time a ... completed.  This FDA approved Phase I/II study builds ... and is an important first step toward the ...
Breaking Biology Technology:Neogen acquires U.K.-based Lab M Holdings 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 4Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 2Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 4
... Analysis -, HOPKINTON, Mass., Dec. 11 ... announced the availability of the,Zephyr SPE Workstation, a ... With features including a 96-well plate format and,easy-to-use, ... to increase efficiency and streamline the sample preparation,process ...
... be Launched in 2008 ... Rosetta Genomics Will use the Licensed Technology in its ... for Sensitive Detection and ... REHOVOT, Israel; NORTH BRUNSWICK, New Jersey, December 11, Rosetta ...
... Mich., Dec. 10 The Perrigo Company,(Nasdaq: PRGO ... Drug,Administration (FDA) has granted final approval to Dexcel Pharma,Technologies, ... marketer and distributor of this product for the store ... to,begin shipping its product during the first quarter of ...
Cached Biology Technology:Caliper Life Sciences Introduces Zephyr SPE Workstation to Improve Efficiency of Solid Phase Extraction 2Rosetta Genomics Selects PCR as Platform for its microRNA-based Diagnostics to be Launched in 2008, Licensed Nanogen's MGB Probe Technology 2Rosetta Genomics Selects PCR as Platform for its microRNA-based Diagnostics to be Launched in 2008, Licensed Nanogen's MGB Probe Technology 3Rosetta Genomics Selects PCR as Platform for its microRNA-based Diagnostics to be Launched in 2008, Licensed Nanogen's MGB Probe Technology 4Perrigo Announces Final FDA Approval of Dexcel's OTC Omeprazole; Raises Full Year Earnings Guidance 2Perrigo Announces Final FDA Approval of Dexcel's OTC Omeprazole; Raises Full Year Earnings Guidance 3
(Date:8/24/2015)... Africa , August 24, 2015 ... Germany ,s largest biometrics manufacturer DERMALOG and its customized ... the "2015 African Biometrics Company of the Year Award". DERMALOG ... Nigeria .   -Cross reference: Picture ... http://www.presseportal.de/nr/8896 - On Thursday evening, in ...
(Date:8/20/2015)... , Aug. 20, 2015 The wearable ... that are active and healthy. However, wearable technology ... hospital environment to help improve diagnostic capabilities and ... from the Wearable Technologies Conference 2015 , ... applications for wearables in healthcare.    ...
(Date:8/20/2015)... ., Aug. 20, 2015 NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... it has joined The Smart Card Alliance and the ... Card Alliance and the Smart Card Alliance Latin America ... to industry peers and thought leaders promoting adoption of ...
Breaking Biology News(10 mins):Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 2Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 3Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4
... in 1990 to emphasize to the general public the ... in our lives. Ullyot Lectures are held annually and ... in their fields, nationally recognized, and able to communicate ... be given by Bernard Bigot, high commissioner of the ...
... breakthrough when they invented a method to test and ... metal particles work much better than others in various ... in fuel cells or reducing automobile pollution. ... journal Nature Materials , also came with a ...
... large-scale models, Molecules That Matter showcases ten organic ... with this fascinating exhibition, five speakersall leaders in ... and the promise and peril of discovery and ... features a range of speakers who will offer ...
Cached Biology News:
... Zyagen tissue microarrays are derived from ... to rigorous quality control procedures to ensure ... are manually assembled in one block, sectioned ... mounted on coated slides. Sections are large ...
... derived from Paraffin embedded tissue blocks, which ... to ensure the highest quality. Tissues of ... block, sectioned at a thickness of 5 ... are large (3-5 mm in diameter) in ...
... derived from Paraffin embedded tissue blocks, which ... to ensure the highest quality. Tissues of ... block, sectioned at a thickness of 5 ... are large (3-5mm in diameter) in comparison ...
... DNA Engine Opticon real-time PCR detection system ... fluorescence excitation (450-495 nm) and a photomultiplier ... Opticon system is built on an DNA ... thermal gradient feature. This item includes the ...
Biology Products: